Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02337517 · ClinicalTrials.gov registry record · Phase 2
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02337517: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02337517 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02337517, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment. Chronic graft-versus-host disease can cause a build-up of scar tissue under the skin and lead to symptoms such as sclerodermatous skin changes, dry mouth, dry eye, narrowing of the esophagus, or vaginal graft-versus-host disease. Vismodegib may work against the build-up of scar tissue and be a better treatment for chronic graft-versus-host disease caused by a hematopoietic stem cell transplant.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Vismodegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-09-08 |
| Est. Completion | 2018-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02337517
The ClinicalTrials.gov registry entry for NCT02337517 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02337517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02337517 about?
NCT02337517 is a clinical study titled "Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease". This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment. Chronic graft-versus-host disease can cause a build-up of scar tissue under the skin and lead to symptoms such as sclerodermatou...
What is the current status of trial NCT02337517?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-09-08. Estimated completion is 2018-06-28.
What interventions are being tested in trial NCT02337517?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Vismodegib (DRUG).
Who is sponsoring clinical trial NCT02337517?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.